Jazz Pharmaceuticals plc — Director's Dealing 2022

Jun 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-06-01

Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-01	Ordinary Shares	M	9700	$46.83	Acquired	358349	Direct
2022-06-01	Ordinary Shares	S	2412	$145.42	Disposed	355937	Direct
2022-06-01	Ordinary Shares	S	1360	$146.05	Disposed	354577	Direct
2022-06-01	Ordinary Shares	S	1270	$148.13	Disposed	353307	Direct
2022-06-01	Ordinary Shares	S	831	$148.82	Disposed	352476	Direct
2022-06-01	Ordinary Shares	S	489	$149.68	Disposed	351987	Direct
2022-06-02	Ordinary Shares	S	1000	$150.0	Disposed	350987	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-01	Non-Qualified Stock Option (right to buy)	$46.83	M	9700	Disposed	2022-08-08	Ordinary Shares (9700)	Direct

Footnotes

F1: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.

F2: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $144.832 to $145.753 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.84 to $146.513 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.62 to $148.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $148.66 to $148.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F8: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.